ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2021. The put-call ratio across all filers is 8.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,687,938 | -23.7% | 75,398 | -1.3% | 0.00% | -25.0% |
| Q2 2023 | $3,524,148 | +53.7% | 76,396 | +33.6% | 0.00% | +33.3% |
| Q1 2023 | $2,292,797 | -14.4% | 57,177 | -1.1% | 0.00% | -25.0% |
| Q4 2022 | $2,678,475 | +11.9% | 57,813 | +0.0% | 0.00% | +33.3% |
| Q3 2022 | $2,393,787 | +67.5% | 57,807 | +141.3% | 0.00% | -25.0% |
| Q2 2022 | $1,429,000 | -24.2% | 23,956 | -7.8% | 0.00% | 0.0% |
| Q1 2022 | $1,886,000 | -57.7% | 25,975 | -51.1% | 0.00% | -55.6% |
| Q4 2021 | $4,463,000 | +178.4% | 53,074 | +198.7% | 0.01% | +200.0% |
| Q3 2021 | $1,603,000 | -7.1% | 17,769 | -1.8% | 0.00% | 0.0% |
| Q2 2021 | $1,725,000 | -45.6% | 18,092 | -35.1% | 0.00% | -50.0% |
| Q1 2021 | $3,173,000 | -15.0% | 27,864 | +3.3% | 0.01% | -25.0% |
| Q4 2020 | $3,733,000 | +130.7% | 26,968 | +37.0% | 0.01% | +100.0% |
| Q3 2020 | $1,618,000 | +5.1% | 19,685 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,540,000 | +28.0% | 19,685 | -27.3% | 0.00% | +33.3% |
| Q1 2020 | $1,203,000 | -90.0% | 27,066 | -90.4% | 0.00% | -88.0% |
| Q4 2019 | $12,081,000 | +5.4% | 282,876 | +5.6% | 0.02% | 0.0% |
| Q3 2019 | $11,458,000 | -33.3% | 267,834 | -1.0% | 0.02% | -32.4% |
| Q2 2019 | $17,175,000 | -36.1% | 270,476 | -30.2% | 0.04% | -38.3% |
| Q1 2019 | $26,864,000 | +158.7% | 387,313 | +62.2% | 0.06% | +130.8% |
| Q4 2018 | $10,384,000 | -61.3% | 238,828 | -32.1% | 0.03% | -52.7% |
| Q3 2018 | $26,842,000 | -18.2% | 351,608 | -17.6% | 0.06% | -21.4% |
| Q2 2018 | $32,807,000 | +3401.3% | 426,788 | +2221.4% | 0.07% | +3400.0% |
| Q1 2018 | $937,000 | +15.1% | 18,385 | +4.7% | 0.00% | 0.0% |
| Q4 2017 | $814,000 | -16.3% | 17,560 | -3.8% | 0.00% | 0.0% |
| Q3 2017 | $972,000 | -90.7% | 18,258 | -89.1% | 0.00% | -91.3% |
| Q2 2017 | $10,422,000 | -4.5% | 167,785 | +4.2% | 0.02% | -8.0% |
| Q1 2017 | $10,910,000 | +8.5% | 160,969 | +12.5% | 0.02% | +4.2% |
| Q4 2016 | $10,056,000 | -25.6% | 143,020 | -25.0% | 0.02% | -7.7% |
| Q3 2016 | $13,520,000 | +86.7% | 190,594 | +28.7% | 0.03% | +44.4% |
| Q2 2016 | $7,241,000 | -17.0% | 148,063 | +7.5% | 0.02% | -18.2% |
| Q1 2016 | $8,723,000 | -63.3% | 137,794 | -35.0% | 0.02% | -62.1% |
| Q4 2015 | $23,773,000 | +1395.2% | 211,924 | +1183.3% | 0.06% | +1350.0% |
| Q3 2015 | $1,590,000 | -12.5% | 16,514 | -7.0% | 0.00% | 0.0% |
| Q2 2015 | $1,818,000 | – | 17,754 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
| First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
| SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
| Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
| Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
| Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
| FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
| Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
| Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
| Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |